?
當前位置:首頁 > 進風巷 > 「108年南臺灣特殊需求者潔牙比賽」4/19臺南登場 9月失業人數45萬5千人

「108年南臺灣特殊需求者潔牙比賽」4/19臺南登場 9月失業人數45萬5千人

2020-09-21 03:57 [汗腺炎] 來源:西寧春旺照明公司

【財訊快報編輯部】行政院主計總處今日公布08年南南登場9月就業人數1,150萬7千人08年南南登場較上月減少1萬9千人或0.16%。9月失業人數45萬5千人,較上月減少1萬1千人或2.4%。9月非勞動力人數為823萬7千人,較上月增加3萬3千人或0.4%。9月勞動力參與率為59.22%,較上月下降0.16個百分點。9月失業率3.8%,較上月下降0.09個百分點;經調整季節變動因素后之失業率3.74%,較上月上升0.01個百分點。

臺北2019年10月15日 /美通社/ -- 臺灣報導:臺灣特殊需美國美加企業("CanAm")很高興地宣布,臺灣特殊需其第40個EB-5項目 -- 莫利納醫療保健項目 -- 已提前全額返還。截止目前,CanAm已為2,600多個投資者家庭實現了資金返還?,F在,莫利納醫療項目的EB-5投資者,也加入了這個大家庭中。

3450萬美元的EB-5投資款用于重新開發位于加利福尼亞州長灘的新聞電報大樓和米克爾-貝克大廈,共有209,702可出租平方英尺的甲級辦公室空間,整體租賃給莫利納醫療保健公司(一家財富500強公司,通過州和聯邦運營的醫療保健計劃為患者提供服務)。該項目的完成使莫利納醫療保健公司可以僱傭新的全職員工,來服務其不斷擴大的全國性業務和客戶。

莫利納醫療保健項目已在在加州創造了大量新的就業機會,并刺激了加州的經濟發展。莫利納項目的成功開發以及相關的就業崗位創造,預計將使所有EB-5投資家庭有資格獲得美國永久居留權。

CanAm的首席運營長Christine Chen表示:「我們很高興能達到這個新里程碑,并進一步確實我們的業績記錄。這也是我們的一個行業基準。我們一貫的項目篩選方法和徹底的盡職調查,是提供高質量EB-5投資機會的關鍵」。

EB-5投資移民計劃由美國移民局管理。根據該計劃,符合資格的外國投資人投資50萬美元(2019年11月21日后將漲價為90萬美元)到美國高失業率地區的企業,并為美國工人創造或保留至少10個全職就業崗位,就有機會獲得美國「有條件」居留權或兩年臨時簽證。

請上我們的網站瀏覽『EB-5全方位手冊』,并歡迎與我們聯絡:info@canamenterprises.com

關于CanAm:

CanAm美加企業為領先的EB-5區域中心管理者,擁有悠久杰出的項目記錄。憑藉著良好的信譽和名聲,CanAm已為60個項目融資,募集了超過28億美元的EB-5資金。其中,40個項目中的2,600個家庭已實現超過13億美元的本金返還。

媒體聯絡人
Clare Chen
+1 646-825-8722
clarechen@canamenterprises.com
www.canamenterprises.com

相關鏈接 :

http://www.canamenterprises.com

(中央社訊息服務20191015 09:28:03)駐西班牙代表處劉德立大使本(14)日投書西國主流媒體「道理日報」(La Razón) 呼吁西國支持臺灣打擊跨國犯罪,求者潔牙比使臺灣以觀察員身分參與「國際刑警組織」(INTERPOL)體系。

劉大使投書標題是「臺灣參與國際刑警組織:求者潔牙比共建無漏洞之國際安全網絡」(Taiwán en la INTERPOL: por una red de seguridad sin fisuras),他表示,臺灣位居亞太戰略位置擁有2,300萬人民之臺灣,係全球第22大經濟體,第17大國際貿易國,上(2018)年有6,890萬人次旅客進出臺灣,係亞洲人流及物流之真正樞紐,將臺灣隔離于INTERPOL之外,不利全球反恐、網路犯罪、電信詐騙等犯罪之努力。

他也以提及,近來臺灣電信詐嫌遭羈押于西班牙,西國在未與臺灣政府取得共識下,終將渠等引渡至中國。倘臺灣參與該組織,也許此種導致誤解之案例將可避免。

「國際刑警組織」第88屆年會即將于智利圣地牙哥召開,劉大使吁請國際社會支持臺灣以觀察員方式參與,以共建真正安全無漏洞的全球安全網絡。

「道理日報」係西班牙主流媒體,向捍衛民主自由價值,普受政經文化及社會知識分子重視,甚具影響力。

訊息來源:外交部外館消息

本文含多媒體檔 (Multimedia files included): http://www.cna.com.tw/postwrite/Detail/262406.aspx

「108年南臺灣特殊需求者潔牙比賽」4/19臺南登場

賽419臺

Investment to enhance Metro Pacific Hospitals鈥 ability to provide high-quality healthcare and hospital services to patients across the Philippines

MANILA, Philippines--(BUSINESS WIRE)--Metro Pacific Investments Corporation (鈥淢PIC鈥? (PSE: MPI), global investment firm KKR, and GIC, Singapore鈥檚 sovereign wealth fund, announced today the signing of certain definitive agreements under which KKR and an affiliate of GIC (鈥淕IC鈥?, will invest in Metro Pacific Hospital Holdings, Inc. ("Metro Pacific Hospitals" or the 鈥淐ompany鈥? through a series of investments in common shares in Metro Pacific Hospitals and in mandatorily exchangeable bonds issued by MPIC. GIC will restructure its current investment in Metro Pacific Hospitals and will re-invest alongside KKR.

Under the terms of the agreement, the KKR-led consortium will subscribe to Php 5.2 billion (US$ 100.0 million) worth of 41,366,178 new common shares in the Company equivalent to 6.25% of the aggregate par value of the Company. Proceeds from the sale of shares in the Company are expected to be used to support Metro Pacific Hospitals鈥 potential investments in additional hospitals and new healthcare businesses. The capital will also be used to grow the Company鈥檚 existing subsidiaries, associates, and joint ventures.

As part of MPIC's wider financing arrangements, the KKR-led consortium will also invest in a Php 30.1 billion (US$ 580.0 million) mandatorily exchangeable bond issued by MPIC. The exchangeable bond shall grant the KKR-led consortium the right to exchange the bond for 239,932,962 common shares in Metro Pacific Hospitals on the sooner of 10 years or an initial public offering, which may be considered after further development of the business. MPIC plans to use the proceeds of this issuance to reduce its bank borrowings.

Metro Pacific Hospitals is the operator of the largest private hospitals and healthcare network in the Philippines in terms of authorized bed capacity and revenue, with interests in 14 hospitals and approximately 3,200 beds across the country. The Company is focused on delivering high-quality healthcare solutions to patients at a time when more Filipinos are seeking premium medical services, driven by rising per capita incomes and rapid urbanization.

Manuel V. Pangilinan, Chairman of MPIC and Metro Pacific Hospitals, said, "I am delighted that we are able to announce this new partnership in the healthcare sector, which is an extension of our successful relationship with KKR with its investment in Voyager Innovations, a digital technology company of MPIC's sister company PLDT. KKR's record of assisting transformational businesses is well known, and our plans for the future of Metro Pacific Hospitals are ambitious."

Augusto P. Palisoc Jr., President & CEO of Metro Pacific Hospitals, added, "We welcome KKR as a new shareholder. Its cash infusion into Metro Pacific Hospitals will enable us to further grow our network, on our way to our new target of 5,000 beds and 30 hospitals before 2030. We also look forward to accessing KKR鈥檚 various healthcare companies in its global portfolio, to bring over new technologies and processes to improve healthcare services in our country.鈥滭/p>

Jose Ma. K. Lim, President and CEO of MPIC, said, "After much consideration we believe we have found the best way forward for Metro Pacific Hospitals and MPIC with this new partnership with KKR. While we have decided for now to postpone the initial public offering for Metro Pacific Hospitals, I thank all the people involved in helping with this effort. I believe the added dimension KKR brings will help transform the delivery of healthcare services in the Philippines.鈥滭/p>

Ashish Shastry, Co-Head of Asia Pacific Private Equity and Head of Southeast Asia at KKR, said, "Today鈥檚 announcement is not only about bringing operational value and capital support to this business 鈥 it鈥檚 about supporting the impressive doctors, nurses and healthcare practitioners at Metro Pacific Hospitals who help millions of patients across the Philippines. Metro Pacific Hospitals exemplifies the type of high-caliber company KKR looks to work with, and we are thrilled to play a role in the development of the Philippines鈥 healthcare infrastructure. We thank Mr. Pangilinan for the confidence he has placed in us, and are very excited to begin working with Mr. Palisoc and his world-class team.鈥滭/p>

KKR has a long track record of supporting companies in the global healthcare sector. Beyond delivering financial capital, KKR helps companies grow by providing access to the firm's operational expertise, global infrastructure, deep network, and resources from its more than 100 current portfolio companies worldwide. In addition to Metro Pacific Hospitals, KKR has invested in leading technology company Voyager Innovations in the Philippines.

Conditions precedent to completion of the transaction include obtaining the necessary corporate approvals (including customary corporate and internal approvals) and regulatory and third-party consents, approvals and confirmations.

The transactions are expected to complete by the end of 2019. KKR will make this investment from its Asian Fund III.

Bank of America Merrill Lynch and UBS are acting as financial advisors to MPIC and GIC. Milbank LLP and Picazo Buyco Tan Fider & Santos are acting as legal counsels to MPIC and GIC. Simpson Thacher & Bartlett LLP and Sycip Salazar Hernandez & Gatmaitan are acting as legal counsels to KKR.

Disclaimer

NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA.

This press release is not an offer of securities for sale in the United States or elsewhere. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of any proposed offering in the United States or to conduct a public offering of securities in the United States. This press release is not for distribution, directly or indirectly, in or into the United States. There shall be no sale of any of the Company鈥檚 securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under securities laws of such state or jurisdiction.

Forward Looking Statements

This press release may contain 鈥渇orward-looking statements鈥 which are subject to risks and uncertainties that could affect the business and results of operations of MPIC or the MPHHI group. Although MPIC believes that expectations reflected in any forward-looking statements are reasonable, it can give no guarantee of the future performance of MPIC or the MPHHI group, or any actions or events.

About Metro Pacific Investments Corporation

Metro Pacific Investment Corporation is a publicly-listed, infrastructure investment firm in the Philippines, with holdings in Manila Electric Company, Global Business Power, Maynilad Water Services, Inc. and Metro Pacific Tollways Corporation. MPIC also holds investments in MPHHI, the Light Rail Manila Company and Metropac Movers Inc.

About Metro Pacific Hospital Holdings, Inc.

Metro Pacific Hospitals is the operator of the largest private hospitals and healthcare network in the Philippines in terms of authorized bed capacity and revenue, with interests in 14 hospitals nationwide, including eight hospitals in Metro Manila. The Company also has interests in an eight primary care clinics and eight cancer care centers, among other investments in allied healthcare services.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR's investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at聽www.kkr.com聽and on Twitter @KKR_Co.

About GIC

GIC is a leading global investment firm established in 1981 to manage Singapore鈥檚 foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate and infrastructure. In private equity, GIC invests through funds as well as directly in companies, partnering with its fund managers and management teams to help world class businesses achieve their objectives. GIC has investments in over 40 countries and has been investing in emerging markets for more than two decades. Headquartered in Singapore, GIC employs over 1,500 people across 10 offices in key financial cities worldwide.

For more information about GIC, please visit聽www.gic.com.sg聽or follow us on聽LinkedIn.

Contacts

Media:

For MPIC & Metro Pacific Hospitals:

David J. Nicol
EVP & Chief Financial Officer
Tel: +632 8888 0888

Augusto P. Palisoc, Jr.
CEO of MPHHI
Tel: +632 8888 0888

Melody M. Del Rosario
VP, PR & Corp. Comms.
Tel. +632 8888 0888

For KKR:

KKR Asia Pacific
Anita Davis
+852 3602 7335
anita.davis@kkr.com

KKR Americas

Kristi Huller & Cara Major
+1 212 750 8300
media@kkr.com

For GIC:

Mah Lay Choon
Senior Vice President
Corporate Affairs & Communications
+65 6889 6841
mahlaychoon@gic.com.sg

Wei Jun Ong
Associate
Corporate Affairs & Communications
+65 6889 8340
ongweijun@gic.com.sg

(中央社記者張建中新竹15日電)晶圓代工廠臺積電美 國存託憑證(ADR)再創歷史新高08年南南登場達49.91美元08年南南登場相當 臺股每股305.65元,臺積電今天股價也持續走高,早盤 達新臺幣293.5元,同創歷史新天價,市值達7.61兆元 。

臺積電挾製程技術領先優勢,營運接單暢旺,7奈 米產能滿載,推升第3季營收攀高至2930.46億元,改寫 歷史新高紀錄,法人看好,在客戶需求依然強勁下,臺 積電第4季業績可望更上層樓。

法人預期,在5G與高效運算等應用強勁成長,臺積 電明年7奈米製程業績可望持續高度成長,5奈米也將開 始量產貢獻業績,整體營運應可重返長期成長軌道。

臺積電近期在外資大舉買超,股價急遽走高,據統 計,外資近10個交易日買超6萬7363張,帶動臺積電股 價大漲24元,漲幅達9.02%,為大盤指數漲幅1.78%的5 倍以上,市值激增6223億元,為盤面多頭指標。

臺積電ADR于14日延續強勁走勢,達49.91美元,再 創歷史新高,帶動臺積電今天股價進一步走高,達新臺 幣293.5元,市值也攀高至7.61兆元,雙雙創下歷史新 高。(編輯:鄭雪文)1081015

(中央社記者鍾榮峰臺北15日電)汽車零配件大廠東陽 9月自結稅前凈利新臺幣1.21億元,臺灣特殊需今年前9月自結累計 稅前凈利17.82億元,臺灣特殊需每股稅前純益3.18元。東陽指出 ,9月匯兌損失約4011萬元。

展望第4季,東陽表示,迎接旺季來臨,各廠加快 生產排程,穩定出貨,因應市場需求。

法人表示,東陽持續擴展售后維修市場(AM)版圖 ,積極開發新模具,自建電鍍廠,收回部分電鍍件改為 自製,受惠美國景氣持續升溫,今年AM事業可望帶動東 陽業績成長。

東陽日前表示,AM事業以臺灣為發展重心,供應全 球市場,持續優化自動化產線、新產品的模具開發。

從產品比重來看,目前AM和OEM占東陽集團合併營 收比重約7比3。

另外,看好新能源車關鍵部品塑件商機,東陽集團 也投入輕量化技術發展。中國大陸轉投資各廠包括一汽 富維東陽青島廠、天津廠去年已順利量產,今年持續貢 獻獲利。

展望今年業績,法人預估,東陽今年毛利率可望提 升到24.5%到24.8%區間,較去年22.87%成長,今年稅后 獲利有機會超過新臺幣20.5億元,上看20.8億元,較去 年成長6%到8%區間,今年每股純益有機會超過3.5元。 (編輯:楊玫寧)1081015

「108年南臺灣特殊需求者潔牙比賽」4/19臺南登場

求者潔牙比

Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric cancer (mGC) and gastroesophageal junction (GEJ) adenocarcinoma

PARIS -- (BUSINESS WIRE) --

Servier and its partner Taiho Oncology, Inc. (US), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF廬 (trifluridine/tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, platinum, and either a taxane and/or irinotecan-containing regimen, and if appropriate, HER2/neu-targeted therapy, were published in the October issue of JAMA Oncology.1

In the preplanned subgroup analysis, 221 of 507 patients with mGC or GEJ adenocarcinoma with prior gastrectomy were enrolled and randomized to receive LONSURF (n=147) or placebo (n=74) on days 1-5 and 8-12 of each 28-day treatment cycle. Results showed that treatment with LONSURF was tolerable and prolonged survival versus placebo by 6 months vs 3.4 months [95% CI, 0.57 (0.41-0.79)]. Further, the overall safety profile of the drug, including the incidence of severe AEs in this heavily pretreated patient population, was similar in patients with or without gastrectomy.

鈥淔or patients with metastatic gastric cancer and gastroesophageal junction adenocarcinoma, nearly half will undergo a gastrectomy and often these patients are likely to have more complications compared to those who do not have one. Therefore this data is critical in demonstrating the safety and efficacy for a large sub-population of patients, who in Europe, may have limited treatment options,鈥 said Professor Josep Tabernero, Head of the Medical Oncology Department, Vall d鈥橦ebron University Hospital, Barcelona and Director of the Vall d鈥橦ebron Institute of Oncology (VHIO).

鈥淧atients with metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, have a high unmet medical need when the current standard of care no longer works. We are pleased with the results from this subgroup analysis that strongly suggest the same efficacy and tolerability for LONSURF in this group of patients regardless of previous gastrectomy,鈥 said Patrick Therasse, MD, PhD, Head of Servier Research and Development Oncology.

Data from the subgroup analysis were previously announced at an oral presentation during the 2019 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco, US.

In the EU LONSURF is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. It has recently been accepted by the European Commission as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

#ENDS#

About TAGS

TAGS (TAS-102 Gastric Study) is a Taiho-sponsored, global, randomized, double-blind, placebo controlled, Phase III study evaluating the efficacy and safety of LONSURF in 507 adult patients with previously treated mGC or mGEJ adenocarcinoma. The primary endpoint was OS, and key secondary endpoints included PFS, safety and tolerability, as well as quality of life. LONSURF demonstrated statistically significant improvements in OS and PFS compared with placebo. The median OS improved from 3.6 months with placebo to 5.7 months with LONSURF, HR 0.69 (95% confidence interval [CI], 0路56-0路85; P=0.00058).

For more information on TAGS, please visit www.ClinicalTrials.gov ( /uploads/2019-11-20/NCT02500043 ). The ClinicalTrials.gov Identifier is NCT02500043.

About Metastatic Gastric Cancer

Gastric cancer, also known as stomach cancer, is a disease in which malignant cells form in the lining of the stomach. It is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and colorectal cancer), with an estimated 780,000 deaths annually.2銆€

When cancer spreads it is called advanced cancer. Locally advanced cancer is when the cancer has grown outside the organ it started in but hasn鈥檛 spread to other parts of the body. When the cancer spreads to other parts of the body, this is called metastatic cancer. In the last two decades, the proportion of patients with gastric cancer who present with metastases has risen to over 40%.3

Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes (with ramucirumab), or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2/neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, there are neither approved nor standard third-line treatments in the EU.

About LONSURF4

LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.

In the EU, LONSURF is indicated in monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. As of October 2019, LONSURF is approved as a treatment for advanced mCRC in 74 countries and regions. LONSURF was approved as a treatment for mGC/mGEJC in the United States in February 2019, in Japan in August 2019 and in the EU in September 2019.

LONSURF was discovered and developed by Taiho Pharmaceutical. In June 2015, Taiho Pharmaceutical and Servier entered into an exclusive license agreement for the co-development and commercialization of LONSURF in Europe and other countries outside of the United States, Canada, Mexico and Asia.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier鈥檚 constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier鈥檚 long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastrointestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics and immune targeted therapies, to deliver life-changing medicines to patients.

More information: www.servier.com

Follow us on Social Media:

LinkedIn

Facebook

Twitter

About Taiho Oncology, Inc. (U.S.)

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the US Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It鈥檚 our work; it鈥檚 our passion; it鈥檚 our legacy.

For more information about Taiho Oncology, please visit: /uploads/2019-11-20/404

For more information about Taiho Pharmaceutical Co., Ltd., please visit: https://www.taiho.co.jp/en/.

For more information about Otsuka Holdings Co., Ltd., please visit: https://www.otsuka.com/en/.

1. Ilson D, Tabernero J, Prokharau A, et al. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. Subgroup Analyses of a Randomized Clinical Trial. JAMA Onc. 2019. doi:10.1001/jamaoncol.2019.3531. Last accessed October 2019.

2. World Health Organization. Globocan (2018), gastric cancer. Available at: /uploads/2019-11-20/7-Stomach-fact-sheet.pdf Last accessed October 2019.

3. Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056鈥?0.

4. European Medicines Agency. LONSURF summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf. Last accessed October 2019.

View source version on businesswire.com: /uploads/2019-11-20/p

CONTACT:

Servier Media Relations

Sonia Marques
sonia.marques@servier.com
Tel.: +33 (0)1 55 72 40 21 / + 33 (0)7 84 28 76 13

Jean-Cl茅ment Vergeau
jean-clement.vergeau@servier.com
Tel.: +33 (0)1 55 72 46 16 / +33 (0)6 79 56 75 96

對決高通 蔡明介加大投資力道,賽419臺聯發科能重返榮耀?▲高通現在正在竹科加緊興建研發大樓,賽419臺離聯發科總部只有5分鐘車程。(圖/財訊雙週刊提供)幾年前,聯發科在高階晶片布局錯誤,讓聯發科和高通在中國的市占率從此反轉;今年,聯發科逆勢加大技術投資,高通和聯發科將在5G晶片市場,掀起新一輪大戰。

明年第一季,5G手機將出現高成長,聯發科能突破「高通障礙」,再次重返榮耀嗎?9月20日,聯發科董事長蔡明介公開展示聯發科的5G單晶片產品,向外界證明,「聯發科5G單晶片已經準備好了!」

蔡明介笑得開懷,因為聯發科員工人數只有高通約1/3,但這一次,聯發科和高通推出5G單晶片時間,都將落在明年第1季。上次4G上線時,聯發科落后高通4年才推出4G晶片,聯發科和對手的差距已拉近。

再仔細看,蔡明介對外展示的產品,不只是一顆晶片,而是「5G單晶片平臺」,除了5G單晶片,還包括了射頻(RF)晶片、Wi-Fi晶片、主電源晶片、次電源晶片、降壓轉換晶片,六顆一組的平臺。換句話說,未來1支5G手機,聯發科有機會一次賣掉6顆晶片?,F在,聯發科5G晶片已進入測試階段。

各方證據顯示,5G普及的速度,將比4G更快!也很快就會進入中階手機的價格戰。IDC(國際數據資訊)9月9日的報告中指出,許多國家2019年已展開5G商用,「2020年將是5G放量成長的1年?!箞蟾嬷蓄A期,明年5G手機出貨量將達1.2億支,占全球手機8.9%,到了2023年,5G手機將占全球手機出貨量28.1%。

▲聯發科股價大事紀。(圖/財訊雙週刊提供)

目前,研發5G晶片的公司當中,華為和三星都是手機品牌廠,對外銷售晶片的量并不多,聯發科要拿下5G手機晶片的市占率,最大的競爭對手就是高通。今年下半年,兩家公司較勁的場合愈來愈頻繁。

例如,高通在9月23日邀請臺灣媒體到美國圣地牙哥總部採訪,聯發科就搶在9月19日辦5G記者會,高通每年12月都會在夏威夷辦大會公布新產品,聯發科今年也宣布,將在12月宣布5G產品細節,在行銷節奏上愈貼愈近。

聯發科和高通的人才爭奪戰也已開打,竹科展業二路上,高通在竹科興建的研發中心,已經打好地基,本刊採訪得知,高通不等大樓蓋好,已經在新竹招募了1支數百人的團隊,其中不乏來自聯發科的好手,研發中心一旦蓋好,勢必還會再從聯發科挖人。

這些蔡明介都看在眼里,記者會上,聯發科向記者展示聯發科自辦的幼兒園,健身房、餐廳;提到給人才什么樣的空間,蔡明介說,「對外商來說,臺灣就是頂多是一個小的點?,比起外地的公司,我們在總部,讓他(指人才)看到Picture還是不一樣的?!构虡兑馕恫谎钥捎?。

在國際標準制定上,聯發科也想扮演更積極的角色。今年8月,聯發科瑞典籍技術專家約翰松(JohanJohansson)當選3GPP(第3代合作伙伴計畫)RAN2無線存取網路工作組主席,這也是聯發科代表有史以來第1次站上主席位置,這個工作組將決定未來無線網路的部分技術架構,另一個重要的工作組主席,則由高通代表出任。

不過,聯發科在中國大陸手機市場,仍面對高通極為強大的競爭壓力。

回顧過去聯發科曾是中國大陸手機最愛用的晶片品牌,省電和高性價比,讓聯發科嘗到在大陸市場市占率如日中天的榮景。但是2015年聯發科推出的新晶片,卻因為採用的技術耗電但效能不佳,通訊規格不符合電信公司要求,市占率開始發生變化;反觀高通卻抓住中國大陸手機市場高規低價的風潮,擁抱小米等品牌,改寫市場規則。

如今打開中國大陸主要手機品牌網站,現有4G手機包括華為、小米、OPPO、VIVO等大品牌的產品組合中,使用高通晶片的手機,從萬元旗艦到2、3千元臺幣的便宜手機,已經全線展開,像OPPO、VIVO都以高通晶片做為旗艦手機的標準配備。相對地,聯發科晶片主要用在1萬元臺幣以下的中低階機種,各家廠牌雖然都用上了聯發科的晶片,但機型較少。

最常發現聯發科手機晶片的地方,是像印度等新興市場。例如,OPPO推出的RENO 2手機,原本搭載高通晶片,但賣往印度的RENO 2Z和2F則是搭載聯發科的P90和P70晶片,小米也採取同樣作法,目前小米品牌手機里,沒有搭載聯發科晶片的產品,但平價的紅米、REALME品牌,採用聯發科晶片的比率就比母品牌高得多。

但是,高通也已經展開新一輪的施壓動作,本刊採訪得知,高通已把5G手機晶片模組化,仿效當年聯發科的山寨模式,在新興市場到處扶植新品牌。一位業界人士觀察,高通擔心中國廠商在美中貿易戰的狀況下,未來不會付給高通權利金,也定下「分散風險」的政策。

其中最具代表性的,是越南的Vingroup公司,這家越南市值最高的公司,今年6月宣布和高通、富士通簽約,將在越南生產5G手機,并把OPPO和三星視為最大競爭對手,要取代這兩家公司在越南的市場地位。聯發科的應對之道,則是默默地加強研發投資,避免再犯前幾年產品策略的錯誤,以及痛失江山的失誤。

針對外界曾批評,聯發科在繪圖晶片上的表現競爭力不夠,游戲早已是手機最重要的應用,不改善手機游戲表現,就等著錯失訂單。今年第2季,執行長蔡力行也宣布,推出強化游戲表現的新手機晶片G90,「這是新的產品,有更好的IP,比較針對游戲體驗設計,」蔡力行說?,F在,走進聯發科新落成的無線技術研發大樓,一進門,看到的就是手機游戲效能的相關展示。

但光是追趕技術恐怕還不夠。本刊採訪多位分析師指出,5G手機市場價格將快速下降,「聯發科明年上半年就算推出5G晶片,也還是攻高階市場,價格未必有競爭力」他也直言懷疑,如果價格沒有競爭力,聯發科5G晶片能不能放量也有問題,如果要攻中低價5G單晶片,「其他人都做不出來,高通也沒有,聯發科憑什么做得出來?」

但蔡力行已在第2季法說會上表示,「2020年聯發科會有更多的5G單晶片,應用在不同的市場里?!孤摪l科第1款5G晶片,會用最高階的CPU和GPU,但他也預期「5G手機產量和需求會迅速上升,除了高階,也需要完整的系列,滿足客戶需要,已經在進行中?!怪须A晶片的布局,很快就會浮上臺面。

橫在聯發科前面的是一場硬仗,不過,記者會里,蔡明介講的一個小故事,反映了他的信心。他回憶,當年在做光儲存晶片時,日本和歐洲是領先者,競爭對手透過代理商傳話,請聯發科別做了,「應該做不出來」,但那一仗,從此奠定聯發科成為亞洲最大IC設計公司的基礎?,F在,聯發科不斷在拉近和高通的距離,要再次把不可能化為可能。

聯發科能否重返榮耀?今年12月,聯發科和高通各端出什么樣的產品和發展藍圖,就將決定第1輪雙方的勝敗。

▲聯發科的小金雞。(圖/財訊雙週刊提供)相關新聞搶商辦/看好南港與汐止紡織大廠宜進兩年投60億搶大樓退休三寶/從養兒防老到養老防兒銀行信託可設下安全閥僅三成二民眾存退休金專家提出「三寶」順利退休安養

「108年南臺灣特殊需求者潔牙比賽」4/19臺南登場

【財訊快報陳孟朔】美國財經媒體CNBC電視臺報導08年南南登場中國國務院副總理劉鶴可能在這個月底前08年南南登場再度率領經貿代表團到美國首都華盛頓,敲定稍早前與美國達成的兩國首階段貿易協議文本,并就第二階段貿易協議展開談判工作。

另有外電報導,中國期望美國取消原定12月中啟動的另一輪向中國貨加徵關稅計劃。

根據報導,中國希望盡快展開新一回合的中美談判代表會面,以澄清美國總統川普先前稱兩國已達成的首階段貿易協議細節。


中國官媒在報導川普所稱的中美達成首階段貿易協議時,并沒有使用完成首階段貿易協議談判的字眼,也沒有提及中國購買美國農產品一事,只提到談判有很大進展。





【財訊快報劉敏夫】外電報導指出,臺灣特殊需英國央行副行長Jon Cunliffe表示,臺灣特殊需長期低利率存在著可能導致經濟下滑更加惡化的風險。

Cunliffe週一在倫敦發表演說時表示,發達經濟體的長期市場利率下跌部分反映了對長期前景的過度悲觀,也是結構趨勢的一部分。低利率維持更長時間給金融穩定帶來的挑戰是,在這樣的環境下,經濟下滑有惡化的風險。

Cunliffe指出,長期低利率增加了經濟低迷時期管理經濟需求的難度,減少了使用傳統工具放寬貨幣政策的空間。這是因為,鑒于既定的通膨目標以及長期實際利率降低,政策利率在接近其有效下限。


Cunliffe還表示,這種環境還可能導致「承擔的風險上升,金融部門韌性下降」。


這項演說主要關注低利率對金融穩定的影響,Cunliffe并未直接談論英國脫歐或英國央行短期政策,儘管他重申了央行的論調,也就是未來利率的上調幅度將受限。但是他補充稱,貨幣政策「在有效下限并非無能為力?!?/p>



與獨立第三方成立合資企業;
邁進業務重組的重要戰略部署;
進一步加強集團的多元化業務發展


香港, 2019年10月9日 - (亞太商訊) - 朗華國際集團有限公司 (「CBG」,求者潔牙比連同其附屬公司統稱為「集團」;香港交易所股票代號:求者潔牙比8026.HK)欣然宣布集團已與獨立第三方(「合營企業合伙人」)簽署不具約束效力的諒解備忘錄成立合營企業,共同發展前景光明的網上銀行和金融服務業務。是次業務拓展將進一步促進及增強集團的業務多元性,有助推動其業務轉型和長期發展。

該合營企業合伙人提供網上銀行服務,包括開設完全在線用戶帳戶、存款、借貸、全球轉賬、支付、交易平臺、安排投資交易(并不提供交易建議)和發行信用卡等。

擬議建立的合營企業將善用雙方的綜合專業知識、設備和資源,提供多元化銀行和金融服務(包括在線銀行服務),以滿足集團的企業客戶業務需求,即在亞洲、歐洲及其他地區發展銀行業務上的需求,尤其在貿易和供應鏈融資方面及「一帶一路」項目發展的需要。

該合營企業已獲阿斯塔納金融服務監管局(「AFSA」)頒發網上銀行沙盒(電腦安全)許可證。 其提供的產品和服務預計在2020年中期推出,有望推動該合營企業的業務發展。

CBG主席兼執行董事張春華先生總結說:「對于是次集團進軍金融科技領域,我們深感欣喜與期待。在過往數年,集團致力于珠寶貿易和零售、貸款業務及醫藥和保健產品業務等不同領域的多元化發展,為集團創造多渠道收入來源?,F在,我們將進一步擴展到網上銀行業務,這是基于集團已發展成熟的貸款業務的進一步延伸,擴大集團為客戶提供的服務範圍,并大幅提升集團的市場價值。集團擬成立合營企業能使集團再向前邁進一大步,充分善用金融科技和上市平臺完成戰略性業務重組?!?br />
CBG首席執行官兼執行董事鍾靜儀女士補充說:「現在,客戶樂于投入數字化生活,善用網上信息的便利性、移動性和個人性??蛻粝My行業能夠提供快速、無縫、可靠、安全的產品和服務。由此可見,網上銀行將逐漸成為市場主要趨勢。鑒于客戶對網上銀行市場的巨大需求,我們相信是次成立合營企業合作的戰略決策能使本集團捉緊商機,擴大收入來源,為本集團和股東提供最大利益。本集團將繼續展望未來,穩步尋求具吸引力的投資機會,進一步擴大集團收入來源,鞏固集團在各個業務領域的市場地位?!?br />
關于朗華國際集團有限公司
朗華國際集團有限公司(「CBG」)于1999年在開曼群島注冊成立,并于2000年3月在香港聯合交易所GEM上市。自2018年以來,CBG致力于進行業務重組,以擴闊收入基礎的多元性。集團業務遍布珠寶貿易和零售、貸款業務以及醫藥和保健產品業務。

Copyright 2019 ACN Newswire. All rights reserved.

金管會今年7月底公布臺灣首波純網路銀行業者名單,賽419臺包括國家隊「將來銀行」、賽419臺「LINE Bank」以及「樂天國際商銀」等3家業者都獲準設立。至于這3家純網銀,未來在臺灣的市占率如何?能否獲利?金管會主委顧立雄今天(9日)在立法院財委會備詢時表示,以國外經驗來看,市占率不會超過1%。#請聽記者陳林幸虹報導#

純網路銀行在亞洲國家掀起風潮,臺灣也在今年7月底宣布開放3家純網銀執照。立法院財政委員會9日邀請金管會主委顧立雄針對純網銀監理原則以及網路金融交易等安全監管專題報告并備詢。

根據金管會的報告,香港近期已陸續核發8家純網銀執照,新加坡宣布將開放5張執照,韓國除現有2家純網銀外,今年再開放申請設立,顯示純網銀的家數界線并非絕對。金管會主委顧立雄在備詢時也表示,目前臺灣國內開放的3家純網銀都還在籌設中,是否再開放更多純網銀執照,會等到設立后,觀察引發的效應,再來進一步思考。

至于這3家純網銀未來市占率會有多少,能否獲利?顧立雄在答復立委質詢時也表示,參考日本與韓國經驗來看,現有純網銀在當地國家市占率都不高,臺灣預估也不會超過1%。顧立雄說:『(原音)以韓國為例,截至3月底為止,合計的資產占他們全體本國銀行總資產0.96%,存款余額占他們全部銀行的1.24%,放款余額占全部銀行的0.93%,我們以這樣子類似的模式評估,我們開放3家純網銀,應該在近期幾年之內,占銀行總資產比例應該是不會超過1%。存款和放款的余額也差不多這樣的狀況?!?/p>

金管會之前也已表態,反對純網銀未來以不合理的定價妨礙金融市場秩序,也就是「先虧本再來競爭」。顧立雄也表示,為及早監控純網銀流動性風險,修正「金融機構申請參加存款保險審核標準」,將新設金融機構申請加入存款保險的時間,由原來的「開始營業日起六個月內」提前為「自取得主管機關設立許可起,至開始營業后2個月內」,就必須申請,大幅縮短存款保險保障的空窗期。至于為保護個人資料安全,業者在開業后1年內,必須通過并取得資安標準(如:ISO27001) 及個資保護標準(如:BS10012、TPIPAS)等認證。

原始連結

【財訊快報記者巫彩蓮報導】國泰金( 2882 )9月稅后盈余38.3億元08年南南登場累計前9月稅后凈利521.3億元08年南南登場超越去年全年的514.67億元,每股稅后盈余3.86元,6.06億股、每股認購價35元現金增資,認股基準日為10月20日。

國泰金旗下子公司國壽股息入帳接近尾聲,新臺幣兌美元升值,避險成本走高,9月稅后凈利21.1億元,前三季累計稅后凈利305.6億元,每股稅后盈余5.25元,9月FYP為107億元、FYPE為47億元,其中保障型商品累計FYP較去年同期成長25%。

國泰世華銀9月稅后凈利15.5億元,前三季累計稅后凈利191.2億元,每股稅后盈余1.93元;國泰產險9月個體簽單保費18.2億元,穩居市場第二;國泰證券各項業務穩定推展,9月稅后凈利5,703萬元。





【財訊快報陳孟朔】港府啟動《禁止蒙面》惡法,臺灣特殊需令香港局勢進一步惡化之際,臺灣特殊需瑞士舉辦的世界經濟論壇(WEF)公布2019年全球競爭力報告(The Global Competitiveness Report 2019)報告,香港卻是連跳四級來到第三名的位置,冠亞軍分別由新加坡和美國奪下。香港在各項主要指標皆上升,但司法獨立等下跌。中國排名維持在28位。臺灣排名上升1級至第12。

世界經濟論壇(World Economic Forum,WEF)去年開始使用新的全球競爭評比4.0指標(Global Competitiveness Index 4.0),評比指標分為有利環境、人力資本、市場及創新生態系統4大類,各項再分為12個細項。

今年報告共評比141個經濟體,全球前5強依序為新加坡、美國、香港、荷蘭及瑞士,日本排名第6。


香港2019年總分是83.1,排名由去年的第7名升至3。分項指標中,宏觀經濟穩定(Macroeconomic stability)名列全球第一,各項指標上升,基建等排名較前;司法獨立、新聞自由和廉潔得分下跌,但仍在較高水平。




【財訊快報記者王宜弘報導】技嘉( 2376 )公告9月業績,求者潔牙比單月合併營收56.64億元,求者潔牙比較上月下滑7.9%,但較同期成長達25.4%,前三季累計營收460億元,同比減幅收斂至4.1%。

其中,第三季在伺服器出貨以及板卡新品銷售增添動能之下,合併營收來到176.67億元,較上季大增43.4%,年增率達29.6%,同比為今年來首度翻正,創6季新高與史上次高。

因輝達(NVIDIA)與AMD相繼推出高性價比GPU,加上舊卡庫存清理結束,法人評估技嘉第三季顯卡銷售季增率高達20-30%。此外,伺服器第三季進入新一波出貨高峰,今年預估貢獻營業額上探180億元,同比跳增80%,兩大引擎推動第三季營收獲利回升。


技嘉近日股價近月在完成填息之后陷入盤整,近日受大盤不穩定因素影響回落到50元以下,週三(9日)維持平盤附近震蕩,法人預估,該公司今年EPS上探3元,明年攻4.5元。




(責任編輯:木龍骨塑鋼板吊頂)

推薦文章
熱點閱讀
亚洲国产高清在线观看视频,岬奈奈美免费在线观看,飞空精品影院